BlossomHill Therapeutics, Inc.
BLSM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001839970
In the last 90 days, BlossomHill Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by BlossomHill Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 5 filings
- 5 insiders, $15.2M in total
- Open-market sells
- 0 filings
- Insiders trading
- 5
- Net value
- +$15.2M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for BlossomHill Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Gordon Carl L | Director | 2,714,279Indirect | Aug 12, 2026 | 2 |
| OrbiMed Advisors LLC | Director | 2,714,279Indirect | Aug 12, 2026 | 1 |
| OrbiMed Capital GP VIII LLC | Director | 2,714,279Indirect | Aug 12, 2026 | 1 |
| Schmid John P. | Director | 6,000 | Aug 10, 2026 | 1 |
| Cormorant Asset Management, LP | 10% Owner | 3,614,034Indirect | Aug 10, 2026 | 1 |
| Chen Bihua | Director, 10% Owner | 3,614,034Indirect | Aug 10, 2026 | 1 |
| Cormorant Global Healthcare Master Fund, LP | 10% Owner | 3,614,034Indirect | Aug 10, 2026 | 1 |
| Cormorant Private Healthcare Fund III LP | 10% Owner | 3,614,034Indirect | Aug 10, 2026 | 1 |
| Cormorant Private Healthcare Fund V LP | 10% Owner | 3,614,034Indirect | Aug 10, 2026 | 1 |
| Cormorant Private Healthcare Fund VI, LP | 10% Owner | 3,614,034Indirect | Aug 10, 2026 | 1 |
| Agrawal Sundeep | Director | 578,524Indirect | Aug 10, 2026 | 1 |
| Keyes Jason A | Chief Financial Officer | 700 | Aug 10, 2026 | 1 |
| Liptak Vincent Paul | General Counsel | 22,687Indirect | Aug 10, 2026 | 1 |
| Oxnard Geoffrey Raymond | Chief Medical Officer | – | Aug 10, 2026 | 1 |
| Li Yishan | Executive Chairman | 124,779Indirect | Aug 10, 2026 | 1 |
| Cui Jingrong Jean | President and CEO | 124,779Indirect | Aug 10, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 (view filing)4:46 PM ET | Aug 10 | 2 days | Gordon Carl LDirector | PPurchase | +625.0K | $16.00 | +$10.0M | +29.9%2.71M after | Duplicate filing |
| Aug 12, 2026 (view filing)4:43 PM ET | Aug 10 | 2 days | OrbiMed Advisors LLC and 1 otherDirector | PPurchase | +625.0K | $16.00 | +$10.0M | +29.9%2.71M after | |
| Aug 10, 2026 (view filing)6:35 PM ET | Aug 10 | Same day | Schmid John P.Director | PPurchase | +6.00K | $16.00 | +$96.0K | New position6.00K after | |
| Aug 10, 2026 (view filing)6:32 PM ET | Aug 10 | Same day | Chen Bihua and 5 othersDirector, 10% Owner | PPurchase | +312.5K | $16.00 | +$5.00M | +9.5%3.61M after | |
| Aug 10, 2026 (view filing)6:27 PM ET | Aug 10 | Same day | Keyes Jason AChief Financial Officer | PPurchase | +700 | $16.00 | +$11.2K | New position700 after | |
| Aug 10, 2026 (view filing)6:26 PM ET | Aug 7-10 | 3 days | Liptak Vincent PaulGeneral Counsel | PPurchase | +4.70K | $15.89 | +$74.7K | +4.4%111.4K after | 2 lots |